We welcome our readers to the October issue of the VOICE, we hope again packed with interesting and relevant information for patients, colleagues, and any other party interested in reproductive sciences and clinical infertility. October is ...
Now accepting Telehealth appointments. Schedule a virtual visit.
A chemical pregnancy is first suspected if the hCG level on the first pregnancy test is positive but too low. A frequent second sign of chemical pregnancy is when the hCG level does not double within two days. Once hCG levels plummet, it becomes very clear that the pregnancy is not normal.
That, however, does not yet necessarily mean that this pregnancy is, or will be, a chemical pregnancy. It is considered as such only if the abnormal pregnancy exists within the uterine cavity. As noted above, if this pregnancy is located outside of the uterus, it is generally considered an ectopic or extrauterine pregnancy rather than a chemical pregnancy. And during these early days of pregnancy when hCG levels are normally low, it is literally impossible to differentiate between early intrauterine and early ectopic pregnancies.
The difficulty in differentiating between these two diagnoses is further aggravated by the fact that early ectopic/tubal pregnancies can also self-terminate, in a process called tubal abortion. As a consequence, a transient rise in hCG during these early days of a pregnancy when one cannot yet expect to see a pregnancy on ultrasound (i.e., before ca. 1500-2000IU/mL of hCG) may be either a chemical pregnancy (in the uterus) or a tubal abortion and an ultimate differential diagnosis may never become clinically possible. [CHR’s Medical Director and Chief Scientist, Norbert Gleicher, MD in 1992 actually published a study, demonstrating that a differential diagnosis can be made radiographically, Fertil Steril 1992;57(3): 553-558]. But since both conditions are self-limited and do not require further follow-up, once hCG levels have returned to being negative, a differential diagnosis is often not of importance and such a radiographic study, therefore, is not indicated.
This is a part of the December 2019 CHR VOICE.
Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.
DISCOVER YOUR TREATMENT OPTIONS
You Might Also Enjoy...
We welcome our readers to the October issue of the VOICE, we hope again packed with interesting and relevant information for patients, colleagues, and any other party interested in reproductive sciences and clinical infertility. October is ...
We are pleased to welcome you to the first issue of the VOICE for the academic year 2021/2022. A new publishing team has taken over, and differences in style and content distribution will, therefore, become quickly apparent. Hopefully also very apparent...
Struggles to get to the clinic? Trying to reduce your exposure to COVID-19, as well as other contagious illnesses, and still need to see your doctor? Telehealth is safe and easy — receive quality care from anywhere.
In this section we attempt to draw attention to science papers we perceive as potentially important for the basic understanding of reproductive biology and, therefore, may have translational relevance to ...
Millions of people who until only a few decades ago had no chance of genetic parenthood, now have children of their own.
